For years, all the research and drug development around the buzzy gene-silencing technique known as RNA interference has centered on the liver. It is by far the easiest target.

But now, just a few months after the Food and Drug Administration approved the first-ever RNAi-based drug, there are early signs that the field is expanding. And while many public and private companies have eyed the brain as their next target, academic research is actually further along in an unexpected organ: the placenta.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This feels like click bait, to invite me to read an article by sending the link along with other articles and then offering to sell me access to the complete article. Cheap shot guys.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy